BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals LLC has launched a new lidocaine product line, starting with lidocaine 5% in ointment form. The company also expects to launch a transdermal patch formulation upon final FDA approval.
Amneal’s lidocaine 5% ointment is available in a 35.44g tube with child-resistant cap and in a 50g jar. The white, scent-free topical is now shipping through wholesalers, distributors and directly to the trade.
“Lidocaine ointment is our third topical medication and, once approved, the patch will be our first transdermal product,” explained Jim Luce, Amneal Executive Vice President of Sales & Marketing. “These two additions to our portfolio demonstrate our commitment to expand into new, more complex dosage forms valued by our pharmacy customers and their patients.”
Annual U.S. sales of lidocaine ointment were $251 million as of September 2015, according to IMS Health. Lidocaine patch shows sales of $907 million for the same time period.
Visit the Amneal product catalog at www.amneal.com for full lidocaine ointment prescribing information and additional details.
About Amneal Pharmaceuticals LLC
Amneal Pharmaceuticals LLC is a global supplier of generic pharmaceuticals, vertically-integrated across the entire supply chain from R&D to finished goods. Since its inception in 2002, Amneal has invested extensively in R&D resources, manufacturing infrastructure, and strategic expansion opportunities—all contributing to its significant growth. The Company prides itself on its unwavering commitment to quality, strong business relationships, and innovative approach to maximizing value. Amneal is privately-held with U.S. headquarters in Bridgewater, New Jersey and international headquarters in Zug, Switzerland. For more information, please visit www.amneal.com.
All trademarks are property of their respective owners.
